Genes And Gene Products As Immunoadjuvants

作为免疫佐剂的基因和基因产物

基本信息

批准号：
8745330
负责人：
Steven Holland
金额：
$ 204.28万
依托单位：
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/8745330
关键词：
Affect Bronchiectasis Child Coccidioidomycosis Cryptococcus neoformans infection Cutaneous Cystic Fibrosis Cytokine Receptors Cytokine Signaling Disease Drug resistance Drug-sensitive Dysmyelopoietic Syndromes Epidemiology Epigenetic Process Epithelial Etiology Functional disorder Genes Genetic Genus Mycobacterium Histoplasmosis Human Immune Immune response Immunobiology Immunocompromised Host Immunologic Adjuvants In Vitro Infection Inflammatory Interferon Type II Interleukin-12 Lesion Lung Lung diseases Lymphocyte Malignant Neoplasms Microbiology Mutation Mycobacterium Infections Mycoses Nature Organism Outcome Pathogenesis Pathologic Pathway interactions Patients Phagocytes Predisposition Production Proteins Race Regulation Role Salmonella Signal Pathway Syndrome Tuberculosis Tumor Necrosis Factor-alpha Work cytokine cytokine therapy fungus interest interferon gamma receptor interferon gamma receptors interleukin-12 receptor macrophage mycobacterial novel therapeutics pathogen research study response tuberculosis treatment

项目摘要

We are working on the identification, description, and treatment of congenital and acquired syndromes of increased susceptibility to mycobacterial and intracellular fungal infections. The syndromes in which we are interested primarily affect the phagocytes, and are most apparent in the increased susceptibility to nontuberculous mycobacteria. These organisms are thought to be important pathogens only in the immunocompromised host. Therefore, we have sought to identify patients without previously recognized forms of immunocompromise who have these infections and then determine the nature of their susceptibility. In this way we have identified and characterized the pathways involved in the control of mycobacteria and other intracellular pathogens, such as Salmonella, histoplasmosis, coccidioidomycosis, and cryptococcosis as well as nontuberculous mycobacteria. The abnormalities we have already identified center around macrophage/lymphocyte interactions leading to the production of or response to interferon gamma, IL-12, and tumor necrosis factor. In addition, the pathways regulating the response to tumor necrosis factor overlap with the interferon gamma signaling pathways and have been shown to be lesioned in patients with these infections. The study of these "experiments of nature" highlights the critical role of the macrophage/ lymphocyte interaction in control of mycobacteria and other intracellular pathogens, including fungi. These observations have led us to explore cytokine therapies and cytokine modifying therapies that may have broader applications to the treatment of tuberculosis. Over the last year we have continued our focus on the importance of the regulation of inflammatory genes in mycobacterial infections through the study of patients with extrapulmonary fungi. We have identified abnormalities in cytokine receptors and signaling in those with histoplasmosis and coccidioidomycosis as well as as mycobacteria. We have also focused on the syndrome of monocytopenia and mycobacterial disease (MonoMAC), which is due to mutations in GATA2 and also predisposes to myelodysplasia and malignancy.

我们正在研究对分枝杆菌和细胞内真菌感染敏感性增加的先天性和可靠性综合征的识别，描述和治疗。我们感兴趣的综合征主要影响吞噬细胞，并且最明显地对增加无结核分枝杆菌的敏感性最为明显。这些生物只有在免疫功能低下的宿主中才被认为是重要的病原体。因此，我们试图鉴定患有这些感染的免疫功能障碍形式的患者，然后确定其敏感性的性质。通过这种方式，我们已经确定并表征了控制分枝杆菌和其他细胞内病原体的途径，例如沙门氏菌，组织胞浆症，球虫病，加密cocococococococisos，以及无结核的分枝杆菌。我们已经在巨噬细胞/淋巴细胞相互作用周围确定的异常，导致对干扰素γ，IL-12和肿瘤坏死因子产生或反应。此外，调节对肿瘤坏死因子的反应与干扰素伽马信号通路重叠的途径已被证明在患有这些感染的患者中已病变。对这些“自然实验”的研究突出了巨噬细胞/淋巴细胞相互作用在控制分枝杆菌和其他细胞内病原体（包括真菌）中的关键作用。这些观察结果使我们探索了细胞因子疗法和细胞因子修饰疗法，这些疗法可能在结核病治疗中更广泛地应用。在过去的一年中，我们通过研究肺外真菌患者的研究，继续关注炎症基因在分枝杆菌感染中的重要性。我们已经确定了细胞因子受体的异常以及组织质症和球菌病以及分枝杆菌的人的信号传导。我们还专注于单核细胞减少症和分枝杆菌疾病（MONOMAC）的综合征，这是由于GATA2突变引起的，并且易于骨髓增生和恶性肿瘤。